Amedeo Smart

Free Medical Literature Service



Liver Diseases

  Free Subscription


2 Am J Gastroenterol
1 Am J Pathol
7 Anticancer Res
3 Biochem Biophys Res Commun
3 BMC Cancer
1 Cancer Res
2 Dig Dis Sci
1 Gastroenterology
2 Gut
4 Hepatology
7 J Gastroenterol Hepatol
5 J Hepatol
2 N Engl J Med
4 PLoS One
2 Radiology
4 Transplant Proc
1 Transplantation

    Am J Gastroenterol

  1. DANPANICHKUL P, Ng CH, Muthiah M, Suparan K, et al
    From Shadows to Spotlight: Exploring the Escalating Burden of Alcohol-Associated Liver Disease and Alcohol Use Disorder in Young Women.
    Am J Gastroenterol. 2024;119:893-909.
    >> Share

  2. BAJAJ JS, Pimentel M
    Is Hepatic Encephalopathy the First True Disorder of Gut-Brain interaction?
    Am J Gastroenterol. 2024 Apr 22. doi: 10.14309/ajg.0000000000002824.
    >> Share

    Am J Pathol

  3. HU J, Xu H, Ma X, Bai M, et al
    Modulating PCGF4 Stability Is an Efficient Metastasis-Regulatory Strategy Used by Distinct Subtypes of Cancer-Associated Fibroblasts in Intrahepatic Cholangiocarcinoma.
    Am J Pathol. 2024 Apr 24:S0002-9440(24)00160.
    >> Share

    Anticancer Res

  4. WAGNER D, Karitnig R, Wienerroither V, Hau HM, et al
    Sarcopenic Obesity Promotes Recurrence in Patients Undergoing Resection for Colorectal Liver Metastases (CRLM).
    Anticancer Res. 2024;44:2177-2183.
    >> Share

  5. GON H, Komatsu S, Omiya S, Kido M, et al
    The Albumin-bilirubin Grade as Prognostic Indicator for Recurrent Hepatocellular Carcinoma Needing Repeat Liver Resection.
    Anticancer Res. 2024;44:2031-2038.
    >> Share

  6. TSUNEMATSU M, Onda S, Shirai Y, Abe K, et al
    Strategies to Perform Emergency Laparoscopic Partial Liver Resection for Ruptured Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:2171-2176.
    >> Share

  7. SEO SH, Yu JI, Park HC, Yoo GS, et al
    Proton Beam Radiotherapy as a Curative Alternative to Radiofrequency Ablation for Newly Diagnosed Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:2219-2230.
    >> Share

  8. KOIZUMI A, Komatsu S, Omiya S, Yano Y, et al
    Current Roles of Ramucirumab in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2024;44:2055-2061.
    >> Share

  9. IKUTA S, Aihara T, Kasai M, Nakajima T, et al
    Long-term Outcomes of Hepatic Resection Combined With Intraoperative Ablation Versus Hepatic Resection Alone for Multinodular Hepatocellular Carcinoma: Insights from a Single-center Study.
    Anticancer Res. 2024;44:2133-2140.
    >> Share

  10. JUNG JY, Koh SA, Lee KH
    Cold-shock Domain Protein A (CSDA) Influences Hepatocyte Growth Factor-medicated Cell Proliferation and Metastasis in Gastric Cancer Cells.
    Anticancer Res. 2024;44:1973-1981.
    >> Share

    Biochem Biophys Res Commun

  11. HE L, Peng L, Wang L, Jiang X, et al
    Investigation of folate-modified EGCG-loaded thermosensitive nanospheres inducing immunogenic cell death and damage-associated molecular patterns in hepatocellular carcinoma.
    Biochem Biophys Res Commun. 2024;714:149976.
    >> Share

  12. KIM DH, Kwon EJ, Park KG, Jin J, et al
    Acesulfame potassium upregulates PD-L1 in HCC cells by attenuating autophagic degradation.
    Biochem Biophys Res Commun. 2024;711:149921.
    >> Share

  13. YAMAMOTO T, Iizuka Y, Izumi-Yamamoto K, Shirota M, et al
    Overexpression of Slc22a18 facilitates fat accumulation in mice.
    Biochem Biophys Res Commun. 2024;712-713:149922.
    >> Share

    BMC Cancer

  14. LI Y, Gong B, Guo Y, Liu W, et al
    Non-small cell lung cancer and immune checkpoint inhibitor therapy: does non-alcoholic fatty liver disease have an effect?
    BMC Cancer. 2024;24:535.
    >> Share

  15. RAO L, Xu P, Zhang G, Zu R, et al
    Prognostic value of creatine kinase (CK)-MB to total-CK ratio in colorectal cancer patients after curative resection.
    BMC Cancer. 2024;24:543.
    >> Share

  16. HUANG S, Liao Z, He X, Song Z, et al
    Ethanol responsive lnc171 promotes migration and invasion of HCC cells via mir-873-5p/ZEB1 axis.
    BMC Cancer. 2024;24:550.
    >> Share

    Cancer Res

  17. ZHANG R, Li S, Schippers K, Li Y, et al
    Analysis of Tumor-Associated AXIN1 Missense Mutations Identifies Variants That Activate beta-Catenin Signaling.
    Cancer Res. 2024;84:1443-1459.
    >> Share

    Dig Dis Sci

  18. PEMMASANI G, Tremaine W, Karagozian R, John S, et al
    Impact of Cirrhosis Etiology on the Risk for Venous Thromboembolism.
    Dig Dis Sci. 2024 May 3. doi: 10.1007/s10620-024-08440.
    >> Share

  19. THRIFT AP, Nguyen Wenker TH, Godwin K, Balakrishnan M, et al
    An Electronic Health Record Model for Predicting Risk of Hepatic Fibrosis in Primary Care Patients.
    Dig Dis Sci. 2024 May 3. doi: 10.1007/s10620-024-08437.
    >> Share


  20. WANG L, Berger NA, Kaelber DC, Xu R, et al
    Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes.
    Gastroenterology. 2024 Apr 29:S0016-5085(24)00494.
    >> Share


  21. ROCA SUAREZ AA, Plissonnier ML, Grand X, Michelet M, et al
    TLR8 agonist selgantolimod regulates Kupffer cell differentiation status and impairs HBV entry into hepatocytes via an IL-6-dependent mechanism.
    Gut. 2024 May 2:gutjnl-2023-331396. doi: 10.1136/gutjnl-2023-331396.
    >> Share

  22. BREITKOPF-HEINLEIN K, Martinez-Chantar ML
    Targeting hepatic stellate cells to combat liver fibrosis: where do we stand?
    Gut. 2024 Apr 25:gutjnl-2023-331785. doi: 10.1136/gutjnl-2023-331785.
    >> Share


  23. CHOPRA SY, Rawat VL, Ingle MA, Lad SG, et al
    Letter to Editor: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - a randomized controlled trial.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000915.
    >> Share

  24. LI X, Zhang Y, Li S, Shi J, et al
    Macrophage hitchhiking for systematic suppression in postablative multifocal hepatocellular carcinoma.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000903.
    >> Share

  25. ELKRIEF L, Denecheau-Girard C, Magaz M, Praktiknjo M, et al
    Abdominal surgery in patients with chronic noncirrhotic extra hepatic portal vein obstruction: A multicenter retrospective study.
    Hepatology. 2024 Apr 29. doi: 10.1097/HEP.0000000000000901.
    >> Share

  26. KUMAR M, Venishetty S
    Reply: Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis - A randomized controlled trial.
    Hepatology. 2024 Apr 30. doi: 10.1097/HEP.0000000000000916.
    >> Share

    J Gastroenterol Hepatol

  27. ZHONG W, Xu B, Lu Y, Chang J, et al
    Postoperative adjuvant chemotherapy is important for improving long-term survival in patients with colorectal cancer liver metastases undergoing simultaneous resection.
    J Gastroenterol Hepatol. 2024;39:908-919.
    >> Share

  28. PEI X, Jiang W, Li L, Zeng Q, et al
    Mendelian-randomization study revealed causal relationship between nonalcoholic fatty liver disease and osteoporosis/fractures.
    J Gastroenterol Hepatol. 2024;39:847-857.
    >> Share

  29. MAKRI ES, Evripidou K, Polyzos SA
    Circulating leptin in patients with nonalcoholic fatty liver disease-related liver fibrosis: a systematic review and a meta-analysis.
    J Gastroenterol Hepatol. 2024;39:806-817.
    >> Share

  30. ENDO K, Kakisaka K, Abe T, Yusa K, et al
    Positive impact of obesity on the prognosis of liver cirrhosis.
    J Gastroenterol Hepatol. 2024 May 3. doi: 10.1111/jgh.16590.
    >> Share

  31. LEE S, Choi J, Park JH, Lim CY, et al
    Dynamic liver volume change in predicting hepatic decompensation and long-term effects of stereotactic body radiation therapy.
    J Gastroenterol Hepatol. 2024 May 2. doi: 10.1111/jgh.16588.
    >> Share

  32. QI S, Wei X, Zhao J, Wei X, et al
    Performance of MAST, FAST, and MEFIB in predicting metabolic dysfunction-associated steatohepatitis.
    J Gastroenterol Hepatol. 2024 Apr 30. doi: 10.1111/jgh.16589.
    >> Share

  33. CAO QH, Liu H, Yan LJ, Wang HC, et al
    Role of hepatitis B core-related antigen in predicting the occurrence and recurrence of hepatocellular carcinoma in patients with chronic hepatitis B: A systemic review and meta-analysis.
    J Gastroenterol Hepatol. 2024 Apr 30. doi: 10.1111/jgh.16558.
    >> Share

    J Hepatol

  34. FU JT, Liu J, Wu WB, Chen YT, et al
    Targeting EFHD2 Inhibits Interferon-gamma Signaling and Ameliorates Non-Alcoholic Steatohepatitis.
    J Hepatol. 2024 Apr 24:S0168-8278(24)00277-0. doi: 10.1016/j.jhep.2024.
    >> Share

  35. MCGETTIGAN B, Shah V
    J Hepatol. 2024 Apr 25:S0168-8278(24)00283-6. doi: 10.1016/j.jhep.2024.
    >> Share

  36. TAN MY, Su JH
    Exploring Hepatocellular Carcinoma Risks in Sub-Saharan African and Afro-Surinamese Individuals with Chronic Hepatitis B living in Europe.
    J Hepatol. 2024 Apr 26:S0168-8278(24)00287-3. doi: 10.1016/j.jhep.2024.
    >> Share

  37. OLLIVIER-HOURMAND I, Lebedel L, Bartroli Alabau B, Goria O, et al
    Recurrent splanchnic and extrasplanchnic thrombotic events in patients with non-cirrhotic portal vein thrombosis associated with local factors.
    J Hepatol. 2024 Apr 26:S0168-8278(24)00284-8. doi: 10.1016/j.jhep.2024.
    >> Share

  38. YANG L, Niu K, Wang J, Shen W, et al
    Nucleolin lactylation contributes to intrahepatic cholangiocarcinoma pathogenesis via RNA splicing regulation of MADD.
    J Hepatol. 2024 Apr 26:S0168-8278(24)00278-2. doi: 10.1016/j.jhep.2024.
    >> Share

    N Engl J Med

  39. HARRISON SA, Taub R
    A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.
    N Engl J Med. 2024;390:1632-1633.
    >> Share

  40. SABET A
    A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:1632.
    >> Share

    PLoS One

  41. LIN YH, Zhang ZJ, Zhong JQ, Wang ZY, et al
    Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
    PLoS One. 2024;19:e0302155.
    >> Share

  42. BI CQ, Kang T, Qian YK, Kang M, et al
    Upregulation of LHPP by saRNA inhibited hepatocellular cancer cell proliferation and xenograft tumor growth.
    PLoS One. 2024;19:e0299522.
    >> Share

  43. BENGTSSON B, Maucourant C, Sandberg JK, Bjorkstrom NK, et al
    Evaluation of mucosal-associated invariant T-cells as a potential biomarker to predict infection risk in liver cirrhosis.
    PLoS One. 2024;19:e0294695.
    >> Share

  44. YAMABA S, Imai Y, Sugawara K, Uchida Y, et al
    Usefulness of atezolizumab plus bevacizumab as second-line therapy for patients with unresectable hepatocellular carcinoma.
    PLoS One. 2024;19:e0298770.
    >> Share


  45. ZENG QQ, Liang P
    Super-Resolution US Imaging of Focal Nodular Hyperplasia.
    Radiology. 2024;311:e233130.
    >> Share

  46. CHEN LD, Huang ZR, Yang H, Cheng MQ, et al
    US-based Sequential Algorithm Integrating an AI Model for Advanced Liver Fibrosis Screening.
    Radiology. 2024;311:e231461.
    >> Share

    Transplant Proc

  47. KANG SW, Ban JY, Park MS
    Protective Role of Rapamycin in Fibrotic Liver Ischemia/Reperfusion Injury (C57bl/6 Mouse).
    Transplant Proc. 2024;56:672-677.
    >> Share

  48. KANG HG, Park H, Myong GE, Kim WJ, et al
    Beneficial Effect of Rapamycin on Liver Fibrosis in a Mouse Model (C57bl/6 Mouse).
    Transplant Proc. 2024;56:701-704.
    >> Share

  49. BEKKI T, Ohira M, Chogahara I, Imaoka K, et al
    Association of Abdominal Aortic Calcification With the Postoperative Metabolic Syndrome Components After Liver Transplantation.
    Transplant Proc. 2024 Feb 7:S0041-1345(24)00016.
    >> Share

  50. SEO CH, Choi HJ, Na GH
    Liver Transplantation at a Small Volume Center-The Role of Network System.
    Transplant Proc. 2024 Feb 5:S0041-1345(24)00037.
    >> Share


  51. CONCORS SJ, Hernandez PT, O'Brien C, DePaolo J, et al
    Differential Effects of HDAC6 Inhibition Versus Knockout During Hepatic Ischemia-reperfusion Injury Highlight Importance of HDAC6 C-terminal Zinc-finger Ubiquitin-binding Domain.
    Transplantation. 2024 Apr 30. doi: 10.1097/TP.0000000000005042.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016